Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

BONESUPPORT Announces CE-Mark of CERAMENT|V, the First Injectable Vancomycin Eluting Bone Substitute in the Management of Osteomyelitis

LUND, Sweden, April 29, 2015 /PRNewswire/ — BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENT™|V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENT™|V is […]

Read More »

FDA could approve drugs for new uses on less data: draft law

(Reuters) – Draft U.S. legislation released on Wednesday could make it easier for drug companies to win Food and Drug Administration approval of products for new uses. Currently a company with a drug approved for lung cancer must conduct additional studies if it wants to market it for breast cancer. A bill drafted by the […]

Read More »

No Benefit For A Commonly Used Cardiac Device

Once again, after decades of common use, a frequently implanted device has been found to confer no benefit whatsoever over a much less invasive therapy. Cardiologists and radiologists often implant the device, called a retrievable inferior vena cava filter, inside people who are at high risk for developing potentially lethal blood clots. The filter is designed to prevent […]

Read More »

PCMA Statement on Safe Pharmacy Provision in the 21st Century Cures Draft

WASHINGTON, April 29, 2015 /PRNewswire-USNewswire/ — The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding the Energy & Commerce Committee’s draft language on the 21st Century Cures initiative: “While we continue to review the latest draft language, we are pleased the Committee has included new patient protection programs aimed at reducing prescription drug […]

Read More »

FDA approves injection for ‘double chin’ reduction

(Reuters) – The U.S. Food and Drug Administration said on Wednesday it approved an injection for “double chin” reduction, developed by Kythera Biopharmaceuticals Inc. The drug, Kybella, is a formulation of synthetically-derived deoxycholic acid, which destroys fat under the chin, leaving surrounding tissue largely unaffected. Other injectables such as Allergan Inc’s Botox and other dermal […]

Read More »

Boston Scientific says atrial fibrillation device in demand

(Reuters) – Boston Scientific Corp expects more hospitals will be able to offer its new atrial fibrillation treatment starting by the end of the third quarter as it paces the product’s rollout to give physicians time to learn how to use it, its chief executive said. The device, called Watchman, was approved by U.S. regulators […]

Read More »

India’s Wockhardt to recall some drugs made in India after U.S. FDA concerns

(Reuters) – Indian generic drugmaker Wockhardt Ltd said on Tuesday it would recall some drugs manufactured at its two plants in India before the U.S. Food and Drug Administration (FDA) banned those sites due to quality concerns. The FDA banned U.S. exports from Wockhardt’s Waluj and Chikalthana plants in central India in 2013, citing manufacturing […]

Read More »

Progress In Cancer Drug Lifts Merck Earnings, Sending Stock Higher

Like nearly every other company that does any business overseas, pharmaceutical giant Merck saw its revenue take a hit from foreign exchange during the first quarter of 2015. But because the company’s ultimate profit and revenue results were above what Wall Street was expecting to see — and because sales were helped by a promising new […]

Read More »

How Lead Product Dependency Shapes Corporate Strategy In Pharma

A number of recent high-profile events in the pharmaceutical industry have showcased the significance of lead product dependency – that is, the proportion of revenues a company derives from its largest selling drug – on corporate strategy. Indeed, lead product dependency has played an integral role in two recently proposed acquisitions with a combined value […]

Read More »

FDA approves first generic for blockbuster antipsychotic Abilify

The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. Reuters/Jason Reed (Reuters) – The U.S. Food and Drug Administration said it approved the first copycat versions of Otsuka Pharmaceutical Co Ltd’s antipsychotic drug Abilify. Generic versions of the drug have been approved for mental illnesses […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom